ACKNOWLEDGMENTS
We acknowledge Professor Vithoulkas for supervising this case and for his academic guidance.
References
1. Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508-525.
2. Elsaiey A, Rahal N, Chung M, et al. Mastocytosis—a review of disease spectrum with imaging correlation. Cancers (Basel). 2021;13(20):5102.
3. Zanotti R, Giona F, Nicolis E, et al. Systemic mastocytosis: multidisciplinary approach. Mediterr J Hematol Infect Dis. 2021;13(1)
4. Héron A, Papillon V, Dubayle D. Medical, neurobiological, and psychobehavioral perspectives of mastocytosis: a case report. J Med Case Reports. 2021;15:176.
5. Georgin-Lavialle S, Gaillard R, Moura D, Hermine O. Mastocytosis in adulthood and neuropsychiatric disorders. Transl Res. 2016;174:77-85.e1.
6. Matito A, Alvarez-Twose I, Morgado JM, Sanchez-Munoz L, Orfao A, Escribano L. Anaphylaxis as a clinical manifestation of clonal mast cell disorders. Curr Allergy Asthma Rep. 2014;14:450. doi:10.1007/s11882-014-0450-8.
7. Sciumè M, Santoro M, Rossi C, et al. Target therapies for systemic mastocytosis: an update. Pharmaceuticals (Basel). 2022;15(6):738.
8. Ibrahim FA, Abdulla MAJ, Soliman D, Al Sabbagh A, et al. A rare case of systemic mastocytosis with associated hematologic neoplasm (SM-AHN) involving chronic myeloid leukemia: a case report and literature review.Am J Case Rep. 2020;21
. doi:10.12659/AJCR.923354.
9. Jendoubi F, Gaudenzio N, Gallini A, Negretto M, Paul C, Bulai Livideanu C. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50:654-661. doi:10.1111/cea.13592.
10. Reiter A, George TI, Gotlib J. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.Leukemia. 2022.
11. Komi DEA, Rambasek T, Wöhrl S. Mastocytosis: from a molecular point of view. Clin Rev Allergy Immunol. 2017. doi:10.1007/s12016-017-8619-2.
12. Rama TA, Martins D, Gomes N, Pinheiro J, et al. Case report: mastocytosis: the long road to diagnosis. Front Immunol. 2021;12:635909.
13. Georgin-Lavialle S, Gaillard R, Moura D, Hermine O. Mastocytosis in adulthood and neuropsychiatric disorders. Transl Res. 2016;174:77-85.e1.
14. McEwen BS. Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci U S A. 2012;109(Suppl 2):17180-17185.
15. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004;146:1-12.
16. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-1362.
Brown RE, Stevens DR, Haas HL. The physiology of brain histamine.Prog Neurobiol. 2001;63(6):637-672.
17. Siegel GJ, Agranoff BW, Albers RW, et al. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia: Lippincott-Raven; 1999.
18. Jennings SV, Slee VM, Finnerty CC, Hempstead JB, Bowman AS. Symptoms of mast cell activation: the patient perspective. Ann Allergy Asthma Immunol. 2021;127(4):407-409.
19. Witt CM, Lüdtke R, Baur R, et al. Homeopathic medical practice: long-term results of a cohort study with 3981 patients. BMC Public Health. 2005;5:115.
20. Witt C, Keil T, Selim D, et al. Outcome and costs of homoeopathic and conventional treatment strategies: a comparative cohort study in patients with chronic disorders. Complement Ther Med. 2005;13(2):79-86.
21. Stub T, Musial F, Kristoffersen AA, Alræk T, Liu J. Adverse effects of homeopathy, what do we know? A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2016;26:146-163.
22. Brien SB, Harrison H, Daniels J, Lewith G. Monitoring improvement in health during homeopathic intervention. Development of an assessment tool based on Hering’s Law of Cure: the Hering’s Law Assessment Tool (HELAT). Homeopathy. 2012;101:28-37.
23. Strohecker J. Alternative Medicine: The Definitive Guide. Tiburon, CA: Future Medicine Publishing Inc.; 1999.